Medtronic received information via literature regarding aortic biological valve prosthesis versus mechanical valve prothesis in patients younger than 65 years of age.All data were collected from a single center between january 2000 and december 2010.The study population included 224 patients (84 bioprosthetic group, 140 mechanical group) whom were predominantly female with an overall meanage 53 years.Two of the 84 patients in the bioprosthetic group were implanted with medtronic freestyle, and an unspecified number of the 140 patients in the mechanical group were implanted with medtronic ats open pivot.No serial numbers were provided.Among all patients, four early deaths and 16 late deaths occurred.Early in-hospital deaths included two in bioprosthetic group (hemorrhage after ascending aortic rupture, and severe sepsis), and two in the mechanical group (non-cardiac-related).During follow-up there were eight deaths in the bioprosthetic group (3 extracardiac, 1 cardiac, 4 unknown), and eight in the mechanical group (causes not provided).No further details were provided on these deaths.Based on the available information medtronic product was not directly associated with the death(s).Among all bioprosthetic valve patients, adverse events included: reoperation for pure structural valve degeneration, stroke, transient ischemic attack (tia), aneurysm, stenosis, and endocarditis.Among all mechanical valve patients, adverse events included: reoperation rate for prosthetic dysfunction, and major late neurological complications (ischemic or hemorrhagic stroke).Based on the available information medtronic product may have been associated with the adverse event(s).No additional adverse patient effects or product performance issues were reported.
|